Spironolactone is associated with reduced risk of new-onset atrial fibrillation in patients receiving renal replacement therapy

International Journal of Cardiology

Volumn 202, Issue , 2016, Pages 962-966

  Chung, Yi Wei ^a   Yang, Yao Hsu ^c,d   Wu, Cho Kai ^b   Yu, Chih Chieh ^b   Juang, Jyh Ming Jimmy ^b   Wang, Yi Chih ^b   Tsai, Chia Ti ^b   Lin, Lian Yu ^b   Lai, Ling Ping ^b   Hwang, Juey Jen ^b   Chiang, Fu Tien ^b   Chen, Pau Chung ^b   Lin, Jiunn Lee ^b  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Atrial fibrillation; ESRD; Hemodialysis; Spironolactone

Indexed keywords

SPIRONOLACTONE; DIURETIC AGENT;

ADULT; AGED; ARTICLE; ATRIAL FIBRILLATION; CONTROLLED STUDY; DOSE RESPONSE; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPENSITY SCORE; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; TAIWANESE; TREATMENT DURATION; ADOLESCENT; ADVERSE EFFECTS; CHEMICALLY INDUCED; FACTUAL DATABASE; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; REGISTER; RISK FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ATRIAL FIBRILLATION; DATABASES, FACTUAL; DIURETICS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; REGISTRIES; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDIES; RISK FACTORS; SPIRONOLACTONE; YOUNG ADULT;

EID: 84959859505     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.05.167     Document Type: Article

References (29)

1. B.F. Gage, A.D. Waterman, W. Shannon, M. Boechler, M.W. Rich, and M.J. Radford Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation JAMA 285 2001 2864 2870
2. D. Zimmerman, M.M. Sood, C. Rigatto, R.M. Holden, S. Hiremath, and C.M. Clase Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis Nephrol. Dial. Transplant. 27 2012 3816 3822
3. K.L. Chien, T.C. Su, H.C. Hsu, W.T. Chang, P.C. Chen, M.F. Chen, and et al. Atrial fibrillation prevalence, incidence and risk of stroke and all-cause death among Chinese Int. J. Cardiol. 139 2010 173 180
4. M.J. Elliott, D. Zimmerman, and R.M. Holden Warfarin anticoagulation in hemodialysis patients: a systematic review of bleeding rates Am. J. Kidney Dis. 50 2007 433 440
5. V. Wizemann, L. Tong, S. Satayathum, A. Disney, T. Akiba, R.B. Fissell, and et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy Kidney Int. 77 2010 1098 1106
6. M. Wiesholzer, F. Harm, G. Tomasec, G. Barbieri, D. Putz, and P. Balcke Incidence of stroke among chronic hemodialysis patients with nonrheumatic atrial fibrillation Am. J. Nephrol. 21 2001 35 39
7. K.E. Chan, J.M. Lazarus, R. Thadhani, and R.M. Hakim Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients J. Am. Soc. Nephrol. 20 2009 872 881
8. K.E. Chan, J.M. Lazarus, R. Thadhani, and R.M. Hakim Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation J. Am. Soc. Nephrol. 20 2009 2223 2233
9. B. Burstein, and S. Nattel Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation J. Am. Coll. Cardiol. 51 2008 802 809
10. A. Shiroshita-Takeshita, B.J. Brundel, B. Burstein, T.K. Leung, H. Mitamura, S. Ogawa, and et al. Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure Cardiovasc. Res. 74 2007 75 84
11. F. Belluzzi, L. Sernesi, P. Preti, F. Salinaro, M.L. Fonte, and S. Perlini Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients J. Am. Coll. Cardiol. 53 2009 24 29
12. C.T. Tsai, F.T. Chiang, C.D. Tseng, J.J. Hwang, K.T. Kuo, C.K. Wu, and et al. Increased expression of mineralocorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation J. Am. Coll. Cardiol. 55 2010 758 770
13. J. Zhao, J. Li, W. Li, Y. Li, H. Shan, Y. Gong, and et al. Effects of spironolactone on atrial structural remodelling in a canine model of atrial fibrillation produced by prolonged atrial pacing Br. J. Pharmacol. 159 2010 1584 1594
14. R.S. Williams, J.A. deLemos, V. Dimas, J. Reisch, J.A. Hill, and R.H. Naseem Effect of spironolactone on patients with atrial fibrillation and structural heart disease Clin. Cardiol. 34 2011 415 419
15. T.L. Chiang Taiwan's 1995 health care reform Health Policy 39 1997 225 239
16. J.F. Lu, and W.C. Hsiao Does universal health insurance make health care unaffordable? Lessons from Taiwan Health Aff. 22 2003 77 88
17. C.H. Tseng Mortality and causes of death in a national sample of diabetic patients in Taiwan Diabetes Care 27 2004 1605 1609
18. S.D. Browne, J. McMaster, S.A. Rizvi, and S. Ahmed End-stage renal disease with atrial fibrillation: uncharted territory in the modern world of anticoagulants Expert. Opin. Pharmacother. 15 2014 1639 1642
19. THt Everett, E.E. Wilson, S. Verheule, J.M. Guerra, S. Foreman, and J.E. Olgin Structural atrial remodeling alters the substrate and spatiotemporal organization of atrial fibrillation: a comparison in canine models of structural and electrical atrial remodeling Am. J. Physiol. Heart Circ. Physiol. 291 2006 H2911 H2923
20. C.H. Pan, J.L. Lin, L.P. Lai, C.L. Chen, S.K. Stephen Huang, and C.S. Lin Downregulation of angiotensin converting enzyme II is associated with pacing-induced sustained atrial fibrillation FEBS Lett. 581 2007 526 534
21. C.S. Lin, L.P. Lai, J.L. Lin, Y.L. Sun, C.W. Hsu, C.L. Chen, and et al. Increased expression of extracellular matrix proteins in rapid atrial pacing-induced atrial fibrillation Heart Rhythm. 4 2007 938 949
22. D. Li, K. Shinagawa, L. Pang, T.K. Leung, S. Cardin, Z. Wang, and et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure Circulation 104 2001 2608 2614
23. A. Goette, T. Staack, C. Rocken, M. Arndt, J.C. Geller, C. Huth, and et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation J. Am. Coll. Cardiol. 35 2000 1669 1677
24. P. Milliez, X. Girerd, P.F. Plouin, J. Blacher, M.E. Safar, and J.J. Mourad Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism J. Am. Coll. Cardiol. 45 2005 1243 1248
25. K. Swedberg, F. Zannad, J.J. McMurray, H. Krum, D.J. van Veldhuisen, H. Shi, and et al. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure) study J. Am. Coll. Cardiol. 59 2012 1598 1603
26. V. Simopoulos, G. Tagarakis, A. Hatziefthimiou, I. Skoularigis, F. Triposkiadis, V. Trantou, and et al. Effectiveness of aldosterone antagonists for preventing atrial fibrillation after cardiac surgery in patients with systolic heart failure: a retrospective study Clin. Res. Cardiol. 104 2015 31 37
27. Y. Matsumoto, Y. Mori, S. Kageyama, K. Arihara, T. Sugiyama, H. Ohmura, and et al. Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients J. Am. Coll. Cardiol. 63 2014 528 536
28. A. Vukusich, S. Kunstmann, C. Varela, D. Gainza, S. Bravo, D. Sepulveda, and et al. A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients Clin. J. Am. Soc. Nephrol. 5 2010 1380 1387
29. M.P. Schneider, T.A. Hua, M. Böhm, K. Wachtell, S.E. Kjeldsen, and R.E. Schmieder Prevention of atrial fibrillation by renin-angiotensin system inhibition a meta-analysis J. Am. Coll. Cardiol. 55 2010 2299 2307